Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05888831 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT05888831: Active Phase 1 study of Advanced Solid Tumors, sponsored by Bristol-Myers Squibb.
NCT05888831 is a Phase 1 study of Advanced Solid Tumors that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 100 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05888831, a Phase 1 study of Advanced Solid Tumors, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of BMS-986449 alone and in combination with nivolumab in participants with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG BMS-986449
Study Locations (20)
Other
- Local Institution - 0003 - Bordeaux
- Local Institution - 0026 - Bergamo
- Local Institution - 0025 - Roma
- Local Institution - 0018 - Groningen
- Local Institution - 0014 - Madrid
- Local Institution - 0011 - Madrid
California
- Local Institution - 0021 - Los Angeles
Connecticut
- Local Institution - 0007 - New Haven
New Jersey
- Local Institution - 0010 - Hackensack
New York
- Local Institution - 0022 - Lake Success
Bruxelles-Capitale, Région de
- Local Institution - 0016 - Brussels
Oost-Vlaanderen
- Local Institution - 0017 - Ghent
Paris
- Local Institution - 0002 - Villejuif
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-06-06 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 1 |
What the registry record for NCT05888831 still lists
NCT05888831 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT05888831 names 20 study sites across 15 states, led by Other, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05888831 about?
NCT05888831 is a clinical study titled "A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors". The purpose of this study is to evaluate the safety and efficacy of BMS-986449 alone and in combination with nivolumab in participants with advanced solid tumors.
What is the current status of trial NCT05888831?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2023-06-06. Estimated completion is 2026-09-30.
What conditions does trial NCT05888831 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT05888831?
The interventions under investigation include: Nivolumab (DRUG), BMS-986449 (DRUG).
Who is sponsoring clinical trial NCT05888831?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05888831 being conducted?
This trial has 20 study locations across California, Connecticut, New Jersey, New York, Bruxelles-Capitale, Région de. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05888831's enrollment target sits among peer trials
100 80th of 144 higher than 63 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI